Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fufang Shenyan (also known as Fufang Shenyan Tablet or Compound Nephritis Tablet) is a Traditional Chinese Medicine (TCM) compound formulation used for the treatment of various kidney diseases, including chronic glomerulonephritis and IgA nephropathy. The formulation typically integrates several herbal components known for their anti-inflammatory, antioxidant, and immunomodulatory properties, such as *Astragalus membranaceus* (Huangqi), *Panax notoginseng* (Sanqi), and *Rehmannia glutinosa*. It is primarily indicated to reduce urinary protein excretion, alleviate clinical symptoms like edema, and slow the progression of renal dysfunction. Clinical research, including studies conducted by The First Affiliated Hospital of Xi'an Jiaotong University, has focused on its ability to stabilize kidney function and reduce proteinuria in patients with biopsy-proven IgA nephropathy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fufang shenyan (First Affiliated Hospital of Xi'an Jiaotong University).